Evolution of the Average Target: MacroGenics, Inc.

Evolution of the Target Price: MacroGenics, Inc.

Changes in Analyst Recommendations: MacroGenics, Inc.

fd11aa70acaadce69b1c9f73c73a.e4bGuCn4DbiV_EvKd8quen7X9VgmyqBys8ByeWPKSZ8.CeSrwXC5bs_mqyWgNI2fDgeIqhlphpdH_ogfPAj9OegJ6_WOZcpEwPOvOA~3a70b636b67760d20a63bf07d8ef405b
04-10 B. Riley Upgrades MacroGenics to Buy From Neutral, Triples Price Target to $9 From $3 MT
15/08/25 MacroGenics Q2 revenue rises RE
20/05/25 B. Riley Cuts Price Target on MacroGenics to $3 From $5, Keeps Neutral Rating MT
07/11/24 JMP Securities Downgrades MacroGenics to Market Perform MT
01/08/24 BTIG Downgrades MacroGenics to Neutral From Buy MT
31/07/24 B. Riley Downgrades MacroGenics to Neutral From Buy, Adjusts Price Target to $5 From $18 MT
31/07/24 Guggenheim Downgrades MacroGenics to Neutral From Buy; Shares Tumble MT
31/07/24 B. Riley Downgrades MacroGenics to Neutral From Buy, Adjusts Price Target to $5 From $18 MT
10/05/24 BMO Downgrades MacroGenics to Market Perform From Outperform, Price Target at $8 MT
10/05/24 Stifel Downgrades MacroGenics to Hold MT
10/05/24 TD Cowen Downgrades MacroGenics to Hold From Buy MT
26/04/24 B. Riley Securities Initiates MacroGenics With Buy Rating, $25 Price Target MT
09/04/24 TD Cowen Upgrades MacroGenics to Buy From Hold MT
11/03/24 HC Wainwright Adjusts Price Target on MacroGenics to $16 From $14, Maintains Neutral Rating MT
11/03/24 JMP Securities Adjusts Price Target on MacroGenics to $22 From $16, Maintains Market Outperform Rating MT
08/03/24 Stifel Adjusts Price Target on MacroGenics to $29 From $17, Keeps Buy Rating MT
08/03/24 BMO Capital Adjusts Price Target on MacroGenics to $24 From $18, Maintains Outperform Rating MT
04/03/24 BTIG Adjusts Price Target on MacroGenics to $24 From $12, Maintains Buy Rating MT
29/02/24 Barclays Raises Price Target on MacroGenics to $23 From $12, Maintains Overweight Rating MT
14/02/24 HC Wainwright Downgrades MacroGenics to Neutral From Buy, Adjusts Price Target to $14 From $12 MT
24/01/24 JMP Securities Adjusts MacroGenics' Price Target to $16 From $10, Maintains Market Outperform Rating MT
20/12/23 Citigroup Upgrades MacroGenics to Buy From Neutral, Raises Price Target to $13 From $7 MT
13/11/23 HC Wainwright Cuts MacroGenics' Price Target to $12 From $14, Keeps Buy Rating MT
07/11/23 Guggenheim Upgrades MacroGenics to Buy From Neutral, Price Target is $12 MT
11/05/23 JMP Securities Adjusts Price Target on MacroGenics to $10 From $8, Maintains Market Outperform Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+40.33%
+10.79%
+23.51%
+35.78%
+90.61%
+41.85%
+35.91%
-9.62%
-21.53%
+31.01%
Average +27.86%
Weighted average by Cap. +26.29%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
4.810USD
Average target price
6.750USD
Spread / Average Target
+40.33%
High Price Target
9.000USD
Spread / Highest target
+87.11%
Low Price Target
4.000USD
Spread / Lowest Target
-16.84%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

B. Riley
JMP Securities
BMO Capital
Stifel Nicolaus
TD Cowen
HC Wainwright
BTIG
Barclays
Citigroup
Guggenheim
Cowen
SVB Securities LLC
Morgan Stanley
SVB Leerink
SMBC Nikko
Wedbush
Credit Suisse
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
4.810USD
Average target price
6.750USD
Spread / Average Target
+40.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MGNX Stock
  4. Consensus MacroGenics, Inc.